Terence Flynn
Stock Analyst at Morgan Stanley
(4.52)
# 264
Out of 5,154 analysts
237
Total ratings
62.3%
Success rate
16.35%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,290 → $1,313 | $990.33 | +32.58% | 24 | Feb 5, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $269 → $270 | $230.11 | +17.34% | 20 | Feb 5, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $304 → $309 | $369.53 | -16.38% | 12 | Feb 4, 2026 | |
| JNJ Johnson & Johnson | Upgrades: Overweight | $200 → $262 | $240.40 | +8.99% | 28 | Jan 28, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $23 → $20 | $22.11 | -9.54% | 9 | Jan 8, 2026 | |
| NRIX Nurix Therapeutics | Upgrades: Overweight | $15 → $36 | $15.10 | +138.41% | 7 | Jan 8, 2026 | |
| ALMS Alumis | Maintains: Overweight | $22 → $33 | $26.90 | +22.68% | 3 | Jan 7, 2026 | |
| BHVN Biohaven | Maintains: Overweight | $26 → $21 | $9.92 | +111.69% | 5 | Jan 6, 2026 | |
| PFE Pfizer | Maintains: Equal-Weight | $28 → $27 | $27.05 | -0.18% | 21 | Dec 17, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $37 | $60.29 | -38.63% | 12 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $102 | $115.79 | -11.91% | 20 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $57.73 | +116.53% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $516 → $564 | $456.69 | +23.50% | 3 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $6.56 | +37.20% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $54 | $45.41 | +18.92% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $101.50 | +29.06% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $478.16 | -9.03% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $13.60 | -19.12% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $56.50 | -43.36% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $13.44 | -18.15% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $3.04 | +163.16% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $184.87 | +135.84% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $320.66 | - | 2 | Oct 2, 2017 |
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,290 → $1,313
Current: $990.33
Upside: +32.58%
AbbVie
Feb 5, 2026
Maintains: Overweight
Price Target: $269 → $270
Current: $230.11
Upside: +17.34%
Amgen
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $304 → $309
Current: $369.53
Upside: -16.38%
Johnson & Johnson
Jan 28, 2026
Upgrades: Overweight
Price Target: $200 → $262
Current: $240.40
Upside: +8.99%
Arcus Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $22.11
Upside: -9.54%
Nurix Therapeutics
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $15.10
Upside: +138.41%
Alumis
Jan 7, 2026
Maintains: Overweight
Price Target: $22 → $33
Current: $26.90
Upside: +22.68%
Biohaven
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $9.92
Upside: +111.69%
Pfizer
Dec 17, 2025
Maintains: Equal-Weight
Price Target: $28 → $27
Current: $27.05
Upside: -0.18%
Bristol-Myers Squibb Company
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $60.29
Upside: -38.63%
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $115.79
Upside: -11.91%
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $57.73
Upside: +116.53%
Dec 5, 2025
Maintains: Overweight
Price Target: $516 → $564
Current: $456.69
Upside: +23.50%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $6.56
Upside: +37.20%
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $45.41
Upside: +18.92%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $101.50
Upside: +29.06%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $478.16
Upside: -9.03%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $13.60
Upside: -19.12%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $56.50
Upside: -43.36%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $13.44
Upside: -18.15%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $3.04
Upside: +163.16%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $184.87
Upside: +135.84%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $320.66
Upside: -